Get started
Author

Kees Bol

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
2001 · Judith E. Karp, Jeffrey E. Lancet, et al. · Blood · 443
JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
2009 · Janine Arts, Peter King, et al. · Clinical Cancer Research · 226
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).
2017 · Maria Alsina, Valentina Boni, et al. · Journal of Clinical Oncology · 44
Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
2020 · Barbara Pistilli, Hans Wildiers, et al. · Journal of Clinical Oncology · 34
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
2018 · Aurelia H. M. de Vries Schultink, Robert P. Doornbos, et al. · Investigational New Drugs · 34
PDF
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.
2020 · Erika Paige Hamilton, Thierry Petit, et al. · Journal of Clinical Oncology · 31
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
2020 · Aurelia H. M. de Vries Schultink, Kees Bol, et al. · Clinical Pharmacokinetics · 18
Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
2016 · Emiliano Calvo, Maria Alsina, et al. · Cancer Research · 13
Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.
2024 · Chrisann Kyi, Marloes Van Dongen, et al. · Journal of Clinical Oncology · 10
PDF
Abstract OT2-15-01: Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who progressed on previous anti-HER2 ADCs
2022 · Erika Hamilton, Thierry Petit, et al. · Cancer Research · 6
Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC).
2021 · Guillem Argiles, Christiane Jungels, et al. · Journal of Clinical Oncology · 6
814 MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity
2020 · Kees Bol, Wilfred Marissen, et al. · 3
Supplementary Data from JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
2023 · Janine Arts, Peter King, et al.
Data from JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
2023 · Janine Arts, Peter King, et al.
Data from JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
2023 · Janine Arts, Peter King, et al.
Supplementary Data from JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
2023 · Janine Arts, Peter King, et al.
PDF
Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma
2021 · Antoine Hollebecque, Irene Brana, et al. · Molecular Cancer Therapeutics
Works count: 17
Citation count: 868
H-index: 9
I10-index: 9
Year
Topic
Type